# Pizarra — PT-pseudo_d3d6b421d0aa (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3d6b421d0aa
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 8.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.202 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 7.4 ng/mL
  - Prostate volume: 42.65 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8539465 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 43 mL. DRE nodus. csPCa 0.85.

Vitals: weight 74 kg, height 170 cm, BMI 25.6, BP 164/61 mmHg, HR 77 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing assessment of established prostate malignancy alongside a persistent upward PSA trend.

History: At 68 years of age, this self-employed carpentry contractor entered clinical review in early 2023 after an unexpected PSA spike, building upon a prior biopsy bucket marked Positive. He endures marked lower urinary tract obstruction, scoring 30 out of 35 on the IPSS, driven mainly by frequent nighttime urination and a diminished urinary stream that heavily disrupts his everyday activities. Though married, he maintains a solo household; his grown daughter acts as his main point of contact and handles all medical paperwork with his permission. He refrains from tobacco use entirely, leads a largely sedentary routine punctuated by brief walks, and limits alcohol intake to roughly nine units weekly. Unexplained weight loss and skeletal pain are firmly denied. Recent sleep disturbances stem chiefly from nocturia and occupational pressures.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, harboring a distinct firm nodule within the right posterior peripheral zone. Vital signs record a blood pressure of 164/61 mmHg and a steady heart rate of 77 beats per minute. Body mass index registers at 25.6 kg/m². Systemic screening shows no peripheral lymphadenopathy or hepatosplenomegaly.

Patient info: self-employed contractor (carpentry); Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 9 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 30/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.32 +/- 0.19   (95% CI 0.03-0.73)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 0 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=8.6, age=68.0, psad=0.202, dre_ord=1.0, vol=42.65, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.77 ng/mL/yr) against the high PI-RADS score (5) and the prior positive biopsy status. It also could not incorporate the specific DRE finding ("Nodus") or the severity of the LUTS (IPSS 30/35) which are clinical context points.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.32 +/- 0.19). This wide interval suggests the classifier is highly uncertain, which is exacerbated by the fact that the prior biopsy was 'Positive'. A prior positive biopsy significantly changes the interpretation of the current PI-RADS 5 and high csPCa probability (0.8539465), potentially making the 'NO BIOPSY' suggestion dangerously conservative or incorrect.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report confirms high-grade features or excludes clinically significant cancer, it would directly influence the decision.
  <document> PSA history (trend) -> If the trend is rapidly increasing or if the velocity is high, it would increase the urgency for further investigation.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or management plan following the prior positive biopsy.
  <document> laboratory results (full panel) -> This could provide context on PSA density or other markers that might refine the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d3d6b421d0aa", "radiology_report": "RAD-2025-0205 | Multiparametric MRI Prostate | 05 Feb 2025\n\nClinical Indication:\nRe-evaluation of established prostate malignancy. Current PSA 8.6 ng/mL. Prior imaging displayed PI-RADS 5.\n\nFINDINGS:\nProstate volume measures 42.65 mL. A discrete focus sits in the right posterior peripheral zone at the base-to-mid junction, spanning 18 x 15 x 12 mm. The area shows intense DWI restriction with low ADC values, T2 hypointensity, and early focal enhancement on dynamic contrast sequences. Seminal vesicles remain clear. No extraprostatic extension or suspicious pelvic lymphadenopathy is detected.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right posterior peripheral zone.\nPSA density: 0.202 ng/mL/mL.\ncsPCa predicted probability 0.8539465."}

  **psa_trend**
  {"case_id": "PT-pseudo_d3d6b421d0aa", "psa_trend": [{"date": "Apr 2023", "val": 8.6}, {"date": "Oct 2023", "val": 4.4}, {"date": "Mar 2024", "val": 8.4}, {"date": "Aug 2024", "val": 4.1}, {"date": "Feb 2025", "val": 8.6}]}

  **previous_notes**
  {"case_id": "PT-pseudo_d3d6b421d0aa", "previous_notes": [{"date": "20 Feb 2023", "author": "Dr. R. van den Berg (GP)", "text": "Initial workup triggered by an incidental PSA reading of 5.5 ng/mL back in April 2023. Follow-up surveillance showed a steady upward trend, leading to a transrectal ultrasound-guided needle sampling that confirmed adenocarcinoma. With the diagnosis secured and PSA levels continuing to climb, the clinical focus shifted toward specialist review."}]}

  **lab_results**
  {"case_id": "PT-pseudo_d3d6b421d0aa", "laboratory_results": [{"name": "PSA", "val": "8.6 ng/mL", "date": "20 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.38 ng/mL", "date": "20 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "28%", "date": "20 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "20 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.0 x10^9/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "255 x10^9/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "100 umol/L", "date": "20 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "20 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "93 U/L", "date": "20 Jan 2025", "flag": ""}, {"name": "LDH", "val": "212 U/L", "date": "20 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 lesion in the right posterior peripheral zone with intense DWI restriction and focal enhancement.
  - PSA trend: PSA velocity of 0.77 ng/mL/yr, with recent values of 8.6 ng/mL.
  - previous_notes: Prior biopsy was positive, and the patient has an ongoing upward PSA trend.
  - lab_results: PSA is 8.6 ng/mL, and %Free PSA is 28%.

  AGAINST sampling this patient now:
  - lab_results: %Free PSA is 28% (which is generally a favorable marker, though context is needed).

WHERE THIS LEANS
  The retrieved evidence strongly argues for further investigation due to the high-risk MRI finding (PI-RADS 5), the concerning PSA velocity, and the history of a prior positive biopsy. This contradicts the statistical prior of 'NO BIOPSY' by emphasizing the high-risk imaging and clinical trajectory.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk factors: a PI-RADS 5 lesion, a high PSA velocity of 0.77 ng/mL/yr, and a history of a prior positive biopsy. The statistical prior suggesting deferral was overturned by the strong clinical evidence pointing toward a need for re-biopsy to assess the new or evolving lesion.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
